Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 0.63 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.63 |
| ▸ | GRM6 | O15303 | 1/20 | 0.63 |
| ▸ | KMO | O15229 | 1/20 | 0.62 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.57 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.55 |
| ▸ | NOS3 | P29474 | 2/20 | 0.54 |
| ▸ | NOS1 | P29475 | 2/20 | 0.54 |
| ▸ | NOS2 | P35228 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44005 | 1.00 | GRM8 (0.63) | GRM8GRM4GRM6KMOSLC7A5 | |
| SCHEMBL30232038 | 1.00 | GRM8 (0.63) | GRM8GRM4GRM6KMOSLC7A5 | |
| SCHEMBL44004 | 1.00 | GRM8 (0.63) | GRM8GRM4GRM6KMOSLC7A5 | |
| SCHEMBL8083539 | 1.00 | GRM8 (0.63) | GRM8GRM4GRM6KMOSLC7A5 | |
| Hydrochloric Acid SCHEMBL8127068 | 0.98 | GRM8 (0.62) | GRM8GRM4GRM6KMOSLC7A5 | |
| Hydrochloric Acid SCHEMBL6747798 | 0.98 | GRM8 (0.62) | GRM8GRM4GRM6KMOSLC7A5 | |
| Hydrochloric Acid SCHEMBL6747799 | 0.98 | GRM8 (0.62) | GRM8GRM4GRM6KMOSLC7A5 | |
| Dl-Phenylalanine SCHEMBL27765394 | 0.93 | ALPI (0.65) | GRM8GRM4GRM6KMOSLC7A5 | |
| SCHEMBL13660573 | 0.86 | SLC7A5 (0.59) | GRM8GRM4GRM6SLC7A5ALPI | |
| Tyrosine SCHEMBL27411908 | 0.86 | SLC7A5 (0.65) | GRM8GRM4GRM6KMOSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116855-A1 | ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS | PALATIN TECHNOLOGIES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-02 | — | — | US | disclosed |
| US-12459894-B2 | Orally active melanocortin receptor-4 compounds | PALATIN TECHNOLOGIES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250327074-A1 | THE RARE CODON RECODING PLATFORM FOR NONCANONICAL AMINO ACIDS INCORPORATION IN MAMMALIAN CELLS | SHAOXING INSTITUTE, ZHEJIANG UNIVERSITY (CN) | 2025-10-23 | — | — | US | disclosed |
| WO-2025079064-A1 | INTERLEUKIN-17 PEPTIDOMIMETIC INHIBITORS | PEPTICOM LTD. (IL) | 2025-04-17 | — | — | WO | disclosed |
| US-12157778-B2 | Peptides for activation of cell signaling in osteoprogenitor cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-03 | — | — | US | disclosed |
| WO-2024200819-A1 | PROTEASE INHIBITORS FOR CORONAVIRAL INFECTIONS | PROTINHI B.V. (NL) | 2024-10-03 | — | — | WO | disclosed |
| EP-4408454-A1 | PROTEASE INHIBITORS | Protinhi B.V. (NL) | 2024-08-07 | — | — | EP | disclosed |
| US-20230346960-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-02 | — | — | US | disclosed |
| WO-2023052636-A1 | PROTEASE INHIBITORS | PROTINHI B.V. (NL) | 2023-04-06 | — | — | WO | disclosed |
| US-11612663-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-28 | — | — | US | disclosed |
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | PALATIN TECHNOLOGIES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20220363719-A1 | Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides | PALATIN TECHNOLOGIES, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| US-20220313867-A1 | ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220204450-A1 | Orally Active Melanocortin Receptor-4 Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459894-B2 | Orally active melanocortin receptor-4 compounds | MC4R, MC1R, MC3R | GRM8 368/4885GRM4 217/4885GRM6 411/4885 |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | FGF23, FGFR1, FGFR3 | GRM8 2372/4885GRM4 3103/4885GRM6 2626/4885 |
| US-20230346960-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | PDGFA, PDGFRB, TEK | GRM8 3403/4885GRM4 3490/4885GRM6 3232/4885 |
| US-20220313867-A1 | ENGINEERED SCAFFOLDS FOR VASCULARIZED TISSUE REPAIR | FLT4, FLT1, KDR | GRM8 4490/4885GRM4 3869/4885GRM6 4205/4885 |
| US-20220363719-A1 | Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides | MC1R, NPY1R, MC3R | GRM8 895/4885GRM4 1545/4885GRM6 1378/4885 |
| US-12485182-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | PDGFA, PDGFRB, TEK | GRM8 3403/4885GRM4 3490/4885GRM6 3232/4885 |
| US-20260083852-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | PDGFA, DCLRE1A, PDGFRA | GRM8 3835/4885GRM4 3957/4885GRM6 3344/4885 |
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | MC1R, MC3R, MC5R | GRM8 529/4885GRM4 980/4885GRM6 553/4885 |
| US-11612663-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | PDGFA, PDGFRB, TEK | GRM8 3403/4885GRM4 3490/4885GRM6 3232/4885 |
| US-20220204450-A1 | Orally Active Melanocortin Receptor-4 Compounds | MC4R, MC1R, MC3R | GRM8 368/4885GRM4 217/4885GRM6 411/4885 |
| US-20260116855-A1 | ORALLY ACTIVE MELANOCORTIN RECEPTOR-4 COMPOUNDS | MC1R, MC3R, MC5R | GRM8 178/4885GRM4 207/4885GRM6 159/4885 |
| US-12157778-B2 | Peptides for activation of cell signaling in osteoprogenitor cells | ITGB4, ITGA4, ITGB1 | GRM8 2770/4885GRM4 1008/4885GRM6 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.